Physician profile
Rachel Laarman
NPI 1598908444
$6,098.22
in general payments reported to CMS, 2019-2025
22 companies · $1,704 in 2025
The $1,704 reported for 2025 was more than what a typical Pediatric Dermatology provider received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $150 · 2021: $2,435 · 2022: $155 · 2023: $290 · 2024: $984 · 2025: $1,704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,898 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,897.59 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $2,671.53 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $724.12 | 2019-2025 | |
| Abbvie INC. | $361.53 | 2023-2025 | |
| Pfizer INC. | $281.17 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $254.92 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $236.98 | 2019-2021 | |
| Janssen Biotech, INC. | $230.94 | 2023-2025 | Tremfya |
| Incyte Corporation | $225.85 | 2022-2025 | Opzelura |
| Ucb, INC. | $202.48 | 2023-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $166.82 | 2024-2025 | Zoryve |
| Leo Pharma INC. | $159.56 | 2024-2025 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.90 | 2023-2024 | Spevigo |
| Amgen INC. | $85.14 | 2023-2025 | Otezla |
| Organon LLC | $79.73 | 2023-2025 | Hadlima |
| Galderma Laboratories, L.P. | $68.64 | 2019-2025 | Nemluvio |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $66.88 | 2023-2025 | Ilumya |
| Lilly USA, LLC | $58.81 | 2023-2025 | Taltz, Ebglyss |
| Lnhc, INC | $29.06 | 2025 | Zelsuvmi |
| Fresenius Kabi USA, LLC | $24.07 | 2024 | Idacio |
| Krystal Biotech INC | $20.73 | 2025 | Vyjuvek |
| Verrica Pharmaceuticals INC. | $17.19 | 2024 | Ycanth |
| Dermavant Sciences, INC. | $14.17 | 2024 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Laarman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.